(Total Views: 88)
Posted On: 06/16/2021 10:00:49 AM
Post# of 74554

$APRE News Article - Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint https://marketwirenews.com/news-releases/apre...56919.html


My Twitter: WhyteStocks